<DOC>
	<DOCNO>NCT02118688</DOCNO>
	<brief_summary>The purpose randomize clinical trial determine whether risperidone alone , trazodone alone , combination risperidone trazodone superior treatment ICU acquire delirium . The hypothesis combination therapy superior either agent alone treat ICU acquire delirium sustain delirium free time .</brief_summary>
	<brief_title>Efficacy Safety Risperidone Trazodone Monotherapy Combination Therapy Critically Ill Patients With Delirium</brief_title>
	<detailed_description>Delirium define disturbance consciousness characterize acute onset impair cognitive function . Although delirium think common Intensive Care Unit ( ICU ) study evaluate incidence , risk outcomes . It associate increased morbidity , mortality increase cost healthcare system . In addition uncertainty incidence ICU delirium , lack information effect certain pharmacological treatment delirious patient . The rationale study evaluate efficacy safety risperidone alone , trazodone alone , risperidone plus trazodone treatment delirium critically ill patient compare placebo .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Trazodone</mesh_term>
	<criteria>Age great 18 year old admit 24 hour MICU SICU Patients diagnose delirium primary team ( screen positive delirium use CAMICU clinical manifestation delirium ) Patients order asneeded haloperidol receive onetime dose haloperidol within 24 hour randomization Patients must tolerate enteral feeding ( great 20 mL/hour 12 hour ) Patients unlikely survive 24 hour admission ICU Patients admit primary neurological condition injury ( i.e . stroke , active seizure , prolong coma , overdose ) Patients actively participate delirium assessment Patients actively withdraw alcohol narcotic Patients treat antipsychotic trazodone within 30 day prior ICU admission Patients mark baseline prolongation QTc interval ( repeat demonstration QTc interval great 500 millisecond ( msec ) ) Patients history Torsades de Pointes Patients current treatment agent either potential affect increase risk QTc prolongation ( e.g . erythromycin , class Ia , Ic , III antiarrhythmic ) Patients treat neuromuscular blocker Patients haloperidol , risperidone , trazodone contraindicate Pregnant patient patient breastfeed Patients modify Blessed dementia rating scale score ≥4 Informant Questionnaire Cognitive Dysfunction Elderly Score ≥4 Patients inform consent obtain legally authorize representative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>